冬虫夏草及各种发酵虫草菌粉产品药效学差异的文献研究  

Pharmacodynamic Differences in the Literature Research of Cordyceps sinensis and Its Fermented Mycelium

作　　者：姚书文 李钰[2] 陈丽华[2] 管咏梅[2] 朱卫丰[2] 聂鹤云[2] 杨明 

机构地区：[1]江西济民可信金水宝制药有限公司/江西省中药及提取物工程技术研究中心/江西省中药及提取物重点实验室,南昌330096 [2]江西中医药大学现代中药制剂教育部重点实验室,南昌330004

出　　处：《中国药房》2015年第3期294-298,共5页China Pharmacy

基　　金：十二五重大新药创制专项(No.2011ZX09201-201-30);江西省高等学校科技落地计划项目(No.产学研合作KJLD13061)

摘　　要：目的:对比冬虫夏草及各种发酵虫草菌粉产品的药效学差异,为临床合理用药提供文献基础和依据,并促进该类产品的可持续发展。方法:计算机检索中国期刊全文数据库、中文科技期刊全文数据库、万方数据库和Pub Med数据库收录的1979年1月-2012年10月发表的文献,按纳入与排除标准筛选文献、提取资料,并对数据进行归纳、整理和分析。结果:共纳入6 740篇文献,文献数量方面冬虫夏草>百令胶囊>金水宝>至灵胶囊>宁心宝胶囊>心肝宝胶囊。在1 547篇药效学研究文献中,冬虫夏草文献占53.01%,金水宝胶囊(片剂)文献占23.34%。冬虫夏草药效学研究主要涉及治疗肾功能衰竭、肝炎、免疫性疾病等,金水宝胶囊(片剂)药效学研究主要涉及治疗糖尿病肾病、慢性肾功能衰竭、慢性肾炎等。冬虫夏草药效学研究文献1993年后上升较快,并且涉及临床治疗肾脏疾病及免疫系统疾病文献数目明显多于其他系统疾病;金水宝胶囊(片剂)药效学研究文献2002年后涉及临床治疗肾脏疾病文献数目呈大幅度上升。结论:冬虫夏草及各种发酵虫草菌粉产品临床疗效的侧重点有所不同。其药效学研究文献逐渐集中,免疫系统疾病、肾脏疾病、肝脏疾病与呼吸系统疾病是冬虫夏草及发酵虫草菌粉产品研究的热点领域。OBJECTIVE： To compare pharmacodynamic differences of Cordyceps sinensis and its fermented mycelium, provide documentary basis for rational drug use in clinical practice and promote sustainable development of products. METHODS： Retrieved from CNKI, VIP, Wanfang database and PubMed database （Jan. 1979-Oct. 2012） , the literatures were selected according to the inclusion and exclusion criteria. The data of literatures was extracted, and then summarized and analyzed. RESULTS ： A total of 6 740 literatures were included, and the number of literatures was in descending order as C. sinensis〉Bailing capsule〉Jinshui- bao〉Zhiling capsule〉Ningxinbao capsule〉Xinganbao capsule. Among 1 547 pharmacodynamic literatures, C. sinensis literature accounted for 53.01%, and Jinshuibao capsule （tablet） literature accounted for 23.34%. The pharmacodynamic study of C. sinensis mainly involved renal failure, hepatitis, immunological disease, etc. That of Jinshuibao capsule （tablet） mainly involved diabetic nephropathy, chronic renal failure, chronic nephritis, etc. The number of pharmacodynamic literatures of C. sinensis increased rapidly after 1993. The number of literatures about renal disease and disease of immune system was significantly more than that of literatures about other system disease. The number of pharmacodynamic literatures about Jinshuibao capsule （tablet） in the treatment of renal disease showed great increase after 2002. CONCLUSIONS ： C. sinensis and its fermented mycelium have their own stresses on clinical effect. The pharmacodynamic literatures are concentrated gradually. Disease of immune system, renal disease, hepatic dis- ease and respiratory disease are the hotspot of C. sinensis and Fermented mycelium of C. sinensis.

关 键 词：冬虫夏草 发酵虫草菌粉产品 药效学 文献研究 

分 类 号：R195[医药卫生—卫生统计学]